These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22322337)

  • 21. Adjuvants and delivery systems for antifungal vaccines: current state and future developments.
    Portuondo DL; Ferreira LS; Urbaczek AC; Batista-Duharte A; Carlos IZ
    Med Mycol; 2015 Jan; 53(1):69-89. PubMed ID: 25362733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
    Vasilakos JP; Tomai MA
    Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New vaccines: challenges of discovery.
    Mahmoud A
    Microb Biotechnol; 2016 Sep; 9(5):549-52. PubMed ID: 27534704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applications of Immunomodulatory Immune Synergies to Adjuvant Discovery and Vaccine Development.
    Tom JK; Albin TJ; Manna S; Moser BA; Steinhardt RC; Esser-Kahn AP
    Trends Biotechnol; 2019 Apr; 37(4):373-388. PubMed ID: 30470547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvanted influenza vaccines.
    Even-Or O; Samira S; Ellis R; Kedar E; Barenholz Y
    Expert Rev Vaccines; 2013 Sep; 12(9):1095-108. PubMed ID: 24053401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retro-engineering of liposomal vaccine adjuvants: role of a microarray-based screen.
    Pattani A; Malcolm RK; Curran RM
    Vaccine; 2010 Feb; 28(6):1438-9. PubMed ID: 20003925
    [No Abstract]   [Full Text] [Related]  

  • 27. Are we entering a new age for human vaccine adjuvants?
    O'Hagan DT; Fox CB
    Expert Rev Vaccines; 2015 Jul; 14(7):909-11. PubMed ID: 25947042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accelerated vaccine development against emerging infectious diseases.
    Leblanc PR; Yuan J; Brauns T; Gelfand JA; Poznansky MC
    Hum Vaccin Immunother; 2012 Jul; 8(7):1010-2. PubMed ID: 22777091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccine adjuvants.
    Reed SG
    Expert Rev Vaccines; 2013 Jul; 12(7):705-6. PubMed ID: 23885812
    [No Abstract]   [Full Text] [Related]  

  • 31. Fourth International Conference: Modern Vaccines/Adjuvants Formulation--Impact on Future Development: May 15-17 2013, CHUV, Lausanne, Switzerland.
    Tupin E
    Hum Vaccin Immunother; 2013 Sep; 9(9):2009-12. PubMed ID: 23896583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccines for epidemic infections and the role of CEPI.
    Plotkin SA
    Hum Vaccin Immunother; 2017 Dec; 13(12):2755-2762. PubMed ID: 28375764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modern Vaccines/Adjuvants Formulation--Session 2 (Plenary II): May 15-17, 2013--Lausanne, Switzerland.
    Collin N
    Hum Vaccin Immunother; 2013 Sep; 9(9):2015-6. PubMed ID: 23966098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine adjuvants: key tools for innovative vaccine design.
    Riese P; Schulze K; Ebensen T; Prochnow B; Guzmán CA
    Curr Top Med Chem; 2013; 13(20):2562-80. PubMed ID: 24066891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Focus on Vaccine Development.
    Woodland DL
    Viral Immunol; 2015; 28(6):303. PubMed ID: 26133044
    [No Abstract]   [Full Text] [Related]  

  • 36. Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade.
    Stefanakis R; Robertson AS; Ponder EL; Moree M
    PLoS Negl Trop Dis; 2012; 6(10):e1803. PubMed ID: 23145186
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunomodulators as adjuvants for vaccines and antimicrobial therapy.
    Nicholls EF; Madera L; Hancock RE
    Ann N Y Acad Sci; 2010 Dec; 1213():46-61. PubMed ID: 20946578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving vaccine performance with adjuvants.
    Vogel FR
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S266-70. PubMed ID: 10875797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Will Systems Biology Deliver Its Promise and Contribute to the Development of New or Improved Vaccines? Seeing the Forest Rather than a Few Trees.
    Davis MM; Tato CM
    Cold Spring Harb Perspect Biol; 2018 Aug; 10(8):. PubMed ID: 29038119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction.
    Mills KH
    Immunol Lett; 2009 Feb; 122(2):108-11. PubMed ID: 19100777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.